Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment

Journal of Clinical Psychopharmacology

Volumn 36, Issue 6, 2016, Pages 550-553

  Fava, Giovanni A ^a,b   Cosci, Fiammetta ^c   Offidani, Emanuela ^d   Guidi, Jenny ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

antidepressant drugs; behavioral toxicity; iatrogenic comorbidity; switching; withdrawal

Indexed keywords

ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

ADVERSE OUTCOME; BEHAVIOR DISORDER; BEHAVIORAL TOXICITY; COGNITION; COMORBIDITY; CONCEPTUAL FRAMEWORK; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; MENTAL DISEASE; MOOD; PERCEPTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; SEDATION; SYNDROME; CHEMICALLY INDUCED; IATROGENIC DISEASE; MENTAL DISORDERS;

COMORBIDITY; HUMANS; IATROGENIC DISEASE; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 84987864044     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000570     Document Type: Review

References (36)

1. DiMascio A, Shader RI. Behavioral toxicity of psychotropic drugs. I. Definition. II. Toxic effects on psychomotor functions. Conn Med. 1968; 32:617-620.
2. DiMascio A, Giller DR, Shader RI. Behavioral toxicity of psychotropic drugs. 3. Effects on perceptual and cognitive functions. IV. Effects on emotional (mood) states. Conn Med. 1968;32:771-775.
3. DiMascio A, Shader RI, Harmatz GS. Behavioral toxicity of psychotropic drugs. V. Effects on gross behavior patterns. Conn Med. 1969;33:279-281.
4. Perl M, Hall RCW, Gardner ER. Behavioral toxicity of psychiatric drugs. In: Hall RCW, ed. Psychiatric Presentations of Medical Illness. New York: Spectrum Publications; 1980:311-336.
5. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987;48:13-19.
6. Shader RI. Psychiatric Complications of Medical Drugs. New York: Raven Press; 1972.
7. Zito MJ, Safer DJ, Craig TJ. Pharmacoepidemiology of psychiatric disorders. In: Hartzema AG, Tilson HH, Chan KA, eds. Pharmacoepidemiology and Therapeutic Risk Management. Cincinnati: Harvey Whitney Books; 2008:817-854.
8. Zito JM. High-dose benzodiazepine use among long-term users: when will we ever learn? Psychother Psychosom. 2015;84:259-261.
9. Fava GA, Tomba E, Tossani E. Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:306-311.
10. Fava GA, Tossani E, Bech P, et al. Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research. Int J Methods Psychiatr Res. 2014;23(suppl 1):92-101.
11. Offidani E, Fava GA, Sonino N. Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs. CNS Drugs. 2014;28:769-774.
12. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121:404-414.
13. Sani G, Napoletano F, Vohringer PA, et al. Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom. 2014;83:213-221.
14. Offidani E, Fava GA, Tomba E, et al. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom. 2013; 82:132-141.
15. Joseph MF, Youngstrom EA, Soares JC. Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors. Future Neurol. 2009;4:87-102.
16. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84:72-81.
17. Chouinard G, Chouinard VA. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom. 2015;84:63-71.
18. Belaise C, Gatti A, Chouinard VA, et al. Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom. 2014;83:247-248.
19. Fava GA. Rational use of antidepressant drugs. Psychother Psychosom. 2014;83:197-204.
20. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-468.
21. Fava GA, Cosci F, Tomba E. Iatrogenic comorbidity in mental health. Psychother Psychosom. 2015;84(suppl 1):22.
22. Richardson WS, Doster LM. Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol. 2014;67:244-246.
23. Vanderbroucke JP, Psaty BM. Benefits and risks of drug treatments. How to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417-2419.
24. Fava GA, Guidi J, Rafanelli C, et al. The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom. 2015;84:1-3.
25. Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther. 2008; 34:353-365.
26. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975;234:1236-1241.
27. Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom. 2013;82:20-34.
28. Boschloo L, Schoevers RA, Beekman AT, et al. The four-year course of major depressive disorder: the role of staging and risk factor determination. Psychother Psychosom. 2014;83:279-288.
29. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract. 2009;63:1085-1094.
30. Salzman C, Shader RI. Not again: benzodiazepines oncemore under attack. J Clin Psychopharmacol. 2015;35:493-495.
31. Cosci F, Guidi J, Balon R, et al. Clinical methodology matters in epidemiology: not all benzodiazepines are the same. Psychother Psychosom. 2015;84:262-264.
32. Starcevic V, Brakoulias V, Viswasam K, et al. Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom. 2015; 84:379-380.
33. Carvalho AF, Berk M, Hyphantis TN, et al. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom. 2014;83:70-88.
34. Guidi J, Fava GA, Bech P, et al. The Clinical Interview for Depression: a comprehensive review of studies and clinimetric properties. Psychother Psychosom. 2011;80:10-27.
35. Rothschild AJ, Raskin J, Wang CN, et al. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry. 2014;55:1-10.
36. Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016;173:128-137.